News

>> Can­cer research: MYC ant­ago­nist deco­ded in gre­a­ter detail
The cancer factor MYC has been the focus of Markus Hartl's research for years. The biochemist's research group is pursuing an approach that aims to reactivate BASP1 – a natural antagonist of MYC – in tumor cells. A study recently published in the Proceedings of the National Academy of Sciences (PNAS) now shows that this approach can work.

>> Deco­ding the Mole­cu­lar Signa­tu­res of Night Blind­ness
Congenital stationary night blindness (CSNB) is caused by mutations in a specific calcium channel. A comprehensive proteomic study by researchers at the University of Innsbruck now reveals how these mutations trigger complex, mutation-specific molecular changes. For the first time, this work provides a solid foundation for the development of personalized therapeutic approaches.

>> Bio-inspi­red che­mistry for inno­va­tive plant pro­tec­tion pro­ducts
Thomas Magauer's research group has achieved an important breakthrough in natural product chemistry. Using a bio-inspired synthesis approach, the researchers were able to develop a new, efficient method for producing highly effective natural lignans – molecules with great potential for plant protection and sustainable pest control.